Zymeworks Inc. Receives FDA Clearance for Investigational New Drug Application for ZW251, Targeting Hepatocellular Carcinoma
Zymeworks Inc., a clinical-stage biotechnology company, has announced the U.S. Food and Drug Administration (FDA) clearance of their investigational new drug $(IND.AU)$ application for ZW251. This novel glypican 3-targeted antibody-drug conjugate $(ADC)$ is designed to treat hepatocellular carcinoma $(HCC)$, the most common form of primary liver cancer. The IND clearance allows Zymeworks to initiate a Phase 1 clinical trial for ZW251, expected to begin in 2025. This marks the second ADC from Zymeworks' pipeline, utilizing their proprietary topoisomerase 1 inhibitor payload. Preclinical studies have shown ZW251 to have strong anti-tumor activity and a favorable tolerability profile, offering potential improvements over current HCC treatments.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9501215-en) on July 28, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。